ResultsIQ › Latest results › Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited Q2 FY27 results deck summary
NSE: INDSWFTLAB · BSE: 532305
Results deck of 4 Nov 2026, summarised by AI from the filing.
Ind-Swift Q2 FY27 total revenue ₹242.49 cr with operating EBITDA margin at 18.02%, as it guides FY27 revenue growth above 50%.
Key takeaways
- Q2 revenue Total revenue ₹242.49 cr in Q2 FY27 (Q1 FY27: ₹193.71 cr), with operating EBITDA of ₹42.33 cr at an 18.02% margin.
- FY27 guidance Management continues to expect FY27 revenue growth of more than 50% and medium-term EBITDA margin expansion of 200-300 BPS.
- Margin step-up Operating EBITDA margin rose to 18.02% in Q2 FY27 from 17.91% in Q1 FY27, with PAT margin at 13.21%.
- CDMO driver Commercialized CDMO partnerships and own brands are expected to add ₹100-130 Cr incremental revenue in FY27.
- Upgrade risk Samba EU-GMP and PIC/S upgrade is still underway, and export capability depends on its completion.
Ind-Swift Laboratories Limited Q2 FY27 results
As filed: Revenue ₹240 cr (+57% year on year), EBITDA ₹45.5 cr (+300% year on year), PAT ₹34.2 cr (+300% year on year), EBITDA margin 18.9% (+1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹191 cr (+25% year on year), EBITDA ₹33.4 cr (+300% year on year), PAT ₹24.7 cr (+174% year on year), EBITDA margin 17.5% (+1,000 bps). Score 69 of 100, Above trend. Revenue growth was in line with the company's own trend; profit growth was well above it. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹15.7 cr on a year ago, more than the ₹8.0 cr it added the year before. Share price after the results: +63.8% in 30 days (Nifty 500: −3.3%).
- Q4 FY26: Revenue ₹170 cr (+23% year on year), EBITDA ₹20.6 cr, PAT ₹15.1 cr (+22% year on year), EBITDA margin 12.1% (+1,000 bps). Score 48 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate -26%. Profit fell 23% from last quarter. Share price after the results: +49.0% in 28 days (Nifty 500: +0.6%).
- Q3 FY26: Revenue ₹151 cr (+300% year on year), EBITDA ₹4.2 cr, PAT ₹9.5 cr, EBITDA margin 2.8%. Score 75 of 100, Above trend. Revenue growth was well above the company's own trend. Other income 168% of PBT. Share price after the results: +21.0% in 30 days (Nifty 500: −1.1%).
- Q2 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹1.0 cr, PAT ₹8.0 cr, EBITDA margin 0.7% (+1,000 bps). Score 79 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 180% of PBT. Profit fell 11% from last quarter. Share price after the results: −5.6% in 28 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹3.0 cr, PAT ₹9.0 cr (+300% year on year), EBITDA margin 2.0% (+1,000 bps). Score 85 of 100, Above trend. Revenue and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 150% of PBT. Profit fell 96% from last quarter. Share price after the results: +0.1% in 30 days (Nifty 500: +2.2%).
- Q4 FY25: Revenue ₹138 cr (−65% year on year), EBITDA −₹10.0 cr, PAT ₹222 cr, EBITDA margin -7.3% (+217 bps). Score 39 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin rose 217 bps year on year. Tax rate 3%.
- Q3 FY25: Revenue ₹9.0 cr, EBITDA −₹15.0 cr, PAT ₹0.0 cr, EBITDA margin -166.7%. Not scored. Too small to score: quarter revenue ₹9.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
Past price moves after results do not indicate future moves. Not a recommendation.
Ind-Swift Laboratories Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.